MDxHealth SA operates as a molecular diagnostics company in Germany, the Netherlands, Poland, the United States, rest of European Union, and internationally.
The last earnings update was 54 days ago.
Value is all about what a company is worth versus what price it is
available for. If you went into a grocery store and all the bananas were on sale
at half price, they could be considered
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
It is not possible to calculate the future cash flow value for
MDxHealth. This is due to cash flow or dividend data being
unavailable. The share price is
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for
it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing
when they are out of season, or how much your home is worth.
The amount the stock market is willing to pay for
is considered below, and whether this is a fair price.
Price based on past earnings
MDxHealth's earnings available for a low price, and how does
this compare to other companies in the same industry?
MDxHealth's earnings are expected to grow significantly at over 20% yearly.
MDxHealth's revenue is expected to grow by 20% yearly, however this is not considered high growth (20% yearly).
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can
be gauged below. We look back 3 years and see if they were any good at
predicting what actually occurred. We also show the highest and lowest estimates
looking forward to see if there is a wide range.
MDxHealth's performance over the past 5 years by checking for:
Has earnings increased in past 5 years? (1 check)
Has the earnings growth in the last year exceeded that of the
industry? (1 check)
Is the recent earnings growth over the last year higher than the average annual growth over the
past 5 years? (1 check)
Is the Return on Equity (ROE) higher than 20%? (1 check)
Is the Return on Assets (ROA) above industry average? (1 check)
Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent
earnings report. Some checks require at least 3 or 5 years worth of data.
has a total score of
0/6, see the detailed checks below.
Note: We use GAAP Net Income excluding extraordinary items in all our calculations.
Management is one of the most important areas of a company. We look at
unreasonable CEO compensation, how long the team and board of directors have
been around for and insider trading.
TENURE AS CEO
Mr. Michael K. McGarrity, also known as Mike, has been the Chief Executive Officer and Director at MDxHealth SA since February 19, 2019. Mr. McGarrity has more than 25 years of experience in the healthcare industry with a unique combination of device, diagnostics and biotechnology experience. Mr. Michael was the Chief Executive Officer and President of Nanosphere, Inc. since February 08, 2013. Mr. McGarrity served as the Chief Commercial Officer at Nanosphere, Inc., until February 8, 2013. He served as the Vice President of Sales & Marketing at Nanosphere, Inc. He served as the Chief Marketing Officer of Nanosphere, Inc., since October, 2005. Mr. McGarrity has more than 17 years of sales and marketing experience in the medical device industry. Prior to Nanosphere, he worked 13 years at Stryker Corporation. At Stryker, he served in leadership roles in marketing and strategic development, including as a Vice President of Marketing at Stryker Instruments, where he also worked Executive General management responsibility for a newly created business focused on interventional pain management. He has been a Director of Nanosphere, Inc., since February 2013. Michael was most recently the CEO of Sterilis Medical. He also had executive general management responsibility for a newly created business unit focused on interventional spine pain management. Michael received a Bachelor of Arts degree from the University of Notre Dame and began his career in commercial banking.
Insufficient data for Mike to compare compensation growth.
Insufficient data for Mike to establish whether their remuneration is reasonable compared to companies of similar size in Germany.
Management Team Tenure
Average tenure and age of the
management team in years:
The average tenure for the MDxHealth management team is less than 2 years, this suggests a new team.
CEO & Director
Executive VP of Finance & Interim CFO
Wim Van Criekinge
Chief Scientific Officer
Chief Compliance Officer
CFO & Executive VP (Leave of Absence)
Executive Vice President of Sales for North America
Board of Directors Tenure
Average tenure and age of the
board of directors in years:
The average tenure for the MDxHealth board of directors is less than 3 years, this suggests a new board.
MDxHealth SA operates as a molecular diagnostics company in Germany, the Netherlands, Poland, the United States, rest of European Union, and internationally. The company develops and commercializes epigenetic and other molecular tests for cancer assessment and the personalized treatment of patients. Its tests are based on genetic, epigenetic (methylation) and other molecular technologies, and assist physicians with the diagnosis of urologic cancers, prognosis of recurrence risk, and prediction of response to a specific therapy. The company’s product pipeline includes tests for prostate, bladder, kidney, cervical, and brain cancers. Its products include ConfirmMDx, a tissue-based epigenetic test for prostate cancer; SelectMDx, a urine-based mRNA test for prostate cancer; and AssureMDx bladder cancer detection test for patients with unresolved hematuria. The company’s preclinical development products comprise InformMDx, a tissue-based gene expression panel for prostate cancer; SelectMDx assay to a point of care testing platform; and MonitorMDx, a blood-based test for prostate cancer. It has collaboration agreement with 3D Signatures Inc. to evaluate prognostic test candidate for prostate cancer. The company was formerly known as OncoMethylome Sciences SA and changed its name to MDxHealth SA in October 2010. MDxHealth SA was founded in 2003 and is headquartered in Herstal, Belgium.
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.